SPERO THERAP.INC. DL-,001 Logo
US84833T1034
A2H63F
SPRO

SPERO THERAP.INC. DL-,001

Forecast

Buy
  6
Hold
  5
Sell
  2

Discussions in the community

There is no discussion about this asset yet.

Start discussion

  • Spero Therapeutics receives $105 million from KKR unit, stock falls

    Spero Therapeutics entered into a $105 million licensing and financing agreement with subsidiaries of Healthcare Royalty (KKR). HCRx will receive a portion of milestone and royalty payments from GSK’s Utebzi sales and will receive quarterly principal and interest payments from those receipts; after full repayment Spero will retain 35% of subsequent GSK payments. The funds will be used primarily to advance the phase-2 immunology candidate SP001, and Spero’s cash runway has been extended into the second half of 2029. The announcement pushed Spero’s stock down about 12% in premarket trading. » More on de.investing.com


  • Spero Therapeutics secures $105 million financing from KKR unit for SP001 development

    Spero Therapeutics agreed a non‑recourse royalty financing of $105 million with Healthcare Royalty (KKR), assigning part of future milestone and license payments from Utebzi sales. The funds will finance development of SP001, a monoclonal anti‑CD40L antibody intended for Phase 2; simultaneously Spero signed an exclusive licensing agreement with Innovent for SP001. Healthcare Royalty will receive quarterly principal and interest payments from GSK payments, and after repayment Spero will retain 35% of subsequent GSK payments; Spero thereby extends its cash runway into the second half of 2029 and reports a current ratio of 10.5. » More on de.investing.com


  • Spero Therapeutics rises 16% after FDA approval for Utebzi

    Shares of Spero Therapeutics climbed 16% after the FDA approved Utebzi, an oral carbapenem developed with GSK to treat complicated urinary tract infections in adults with limited oral options. Utebzi is the first oral carbapenem approved in the U.S.; the approval is based on the Phase III PIVOT-PO study, which showed noninferiority to intravenous imipenem‑cilastatin. The drug is expected to be available in the U.S. by the end of 2026; development was partially supported by BARDA. » More on de.investing.com


  • Spero Therapeutics: board member Mahadevia resigns, SEC ends investigation

    Dr. Ankit Mahadevia has resigned from the board of Spero Therapeutics with immediate effect and has also relinquished his committee and subsidiary mandates; the company cites other professional commitments for the resignation. Spero plans to engage Mahadevia as a consultant to continue supporting management. The U.S. securities regulator SEC said that, based on available information, it currently does not intend to pursue enforcement actions against Spero. In addition, the FDA’s re‑filing of the NDA for the oral carbapenem tebipenem HBr triggers an expected $25 million milestone payment to Spero in Q1 2026, subject to acceptance of the filing. » More on de.investing.com


  • Spero Therapeutics beats Q2 expectations and stock rises

    Spero Therapeutics reported Q2 2025 EPS of -$0.03 on revenue of $14.2 million, both well above expectations, and the stock rose double‑digit after the results. The company sharply reduced its net loss, extended its financing runway to 2028, and views Tebipenem HBr—after a successful Phase‑3 study—as on track for possible FDA approval in 2026. Challenges remain in the SPR720 program, and dependence on milestone payments continues to be a risk. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2015, SPERO THERAP.INC. DL-,001 has already paid €0.0534 in dividends. The last payout was in October 2015.

Financials

In the last quarter, SPERO THERAP.INC. DL-,001 had revenue of €0 and net profit of -€39.09M

(EUR) September 2026
YoY
Revenue 0 100.00%
Gross profit 0 100.00%
Net profit -39.09M 521.43%
EBITDA -6.1M 2.27%

Fundamentals

Metric Value
Market capitalization
€46.41M
Number of shares
58.26M
52-week high/low
€2.81 - €0.79
Dividends No
Beta
1.56
P/E ratio
-1.78
PEG ratio
0.00
P/B ratio
65.16
P/S ratio
1.28

Company profile

Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, an oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; license agreement with Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; collaboration agreement with Bill & Melinda Gates Medical Research Institute to develop SPR720 for the treatment of lung infections caused by Mycobacterium tuberculosis; and license agreement with Vertex Pharmaceuticals Incorporated for patents relating to SPR720, as well as SPR719, an active metabolite. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Name
SPERO THERAP.INC. DL-,001
CEO
Esther Rajavelu
Headquarters Cambridge, ma
USA
Website
Sector
Materials
Industry
Chemicals
IPO
11/02/2017
Employees 25

Ticker symbols

Exchange Symbol
NASDAQ
SPRO
Frankfurt
2HA.F
DĂĽsseldorf
2HA.DU
MĂĽnchen
2HA.MU
🍪

Parqet  uses cookies. Learn more